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Candida albicans is a dimorphic fungus that colonizes human mucosal surfaces with the
potential to cause life-threatening invasive candidiasis. Studies on systemic candidiasis
in a murine infection model using in vivo real-time bioluminescence imaging revealed
persistence of C. albicans in the gall bladder under antifungal therapy. Preliminary
analyses showed that bile conferred resistance against a wide variety of antifungals
enabling survival in this cryptic host niche. Here, bile and its components were
studied for their ability to reduce antifungal efficacy in order to elucidate the underlying
mechanism of protection. While unconjugated bile salts were toxic to C. albicans,
taurine, or glycine conjugated bile salts were well tolerated and protective against
caspofungin and amphotericin B when exceeding their critical micellar concentration.
Microarray experiments indicated that upregulation of genes generally known to mediate
antifungal protection is not involved in the protection process. In contrast, rhodamine
6G and crystal violet in- and efflux experiments indicated encapsulation of antifungals
in micelles, thereby reducing their bioavailability. Furthermore, farnesol sensing was
abolished in the presence of conjugated bile salts trapping C. albicans cells in the
hyphal morphology. This suggests that bioavailability of amphiphilic and hydrophobic
compounds is reduced in the presence of bile. In contrast, small and hydrophilic
molecules, such as cycloheximide, flucytosine, or sodium azide kept their antifungal
properties. We therefore conclude that treatment of gall bladder and bile duct infections
is hampered by the ability of bile salts to encapsulate antifungals in micelles. As a
consequence, treatment of gall bladder or bile duct infections should favor the use of
small hydrophilic drugs that are not solubilised in micelles.
Keywords: conjugated bile salts, caspofungin, farnesol, rhodamine 6G, critical micelle concentration
INTRODUCTION
The dimorphic fungus Candida albicans is frequently found as a commensal on mucosal surfaces.
In addition, it causes life-threatening systemic infections in patients with risk factors, such as
diabetes, central line catheters, cancer, or organ transplantation (Akpan and Morgan, 2002;
Cassone and Cauda, 2012; Gavalda et al., 2014; Teoh and Pavelka, 2016). To control systemic
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candidiasis, the echinocandin caspofungin, the polyene
macrolide amphotericin B or azoles are commonly used
(Gullo, 2009; Li et al., 2015; Matthaiou et al., 2015). To follow
antifungal therapy efficacy in a systemic murine infection
model an in vivo bioluminescence imaging system was
recently developed that visualizes invasive disease in real-
time and in temporal and spatial resolution (Jacobsen et al.,
2014). Systemic infection revealed a rapid manifestation of
disease in kidneys with bioluminescence signals correlating
with fungal burden. A subsequent therapy approach with
initial caspofungin treatment and fluconazole de-escalation
showed rapid clearance of infection from kidneys, and mice
appeared clinically inconspicuous after initiation of treatment.
Unexpectedly, some mice from the therapy group developed
bioluminescence signals from the gall bladder (Jacobsen et al.,
2014) and living C. albicans cells were shed with the release of
bile from the gall bladder, potentially leading to a re-colonization
of the intestinal tract. Preliminary analyses indicated that bile
decreases the sensitivity of C. albicans against a wide variety of
commonly used antifungals, implying that the gall bladder forms
a protective niche during antifungal therapy (Jacobsen et al.,
2014).
Candida albicans infections of the liver and biliary
system have been described as a major complication in
liver transplant recipients (Romero and Razonable, 2011;
Hernandez Mdel et al., 2015) and a prophylactic therapy
with antifungals, mainly with fluconazole or echinocandins
is recommended (Hernandez Mdel et al., 2015). However,
while a case study on a liver transplant recipient suffering
from Candida cholangitis recommended caspofungin for
treatment of biliary infections (Goicoechea et al., 2004) the
study showed that despite parenteral caspofungin therapy
fluconazole sensitive C. albicans could still be isolated from
bile samples (Goicoechea et al., 2004). Another clinical case
report showed that conventional amphotericin B failed to
control candidemia in the gall bladder (Jajoo et al., 2012)
and in a clinical case series Candida bile duct infections
were linked to treatment failure in some patients (Domagk
et al., 2006). Additional studies indicate that treatment of
fungal infections of the biliary system appears to present a
more general problem. One study showed that antifungal
therapy was ineffective in a biliary Coccidioides immitis
infection (Sydorak et al., 2001). In another case report early
hepatic artery thrombosis due to bacterial and Aspergillus
infection occurred in a liver transplant recipient. Despite
antibiotic and amphotericin B treatment the infection was
not resolved and a revision of liver transplantation was
required. It was speculated that the donor liver was the primary
source of the infection (Jafarian et al., 2014). These studies
indicate that the gall bladder may serve as a fungal infection
reservoir not only in a murine model of candidiasis, but also in
humans.
Due to the reduced susceptibility of C. albicans toward
antifungals in the presence of bile and the described
problems of antifungal therapy in biliary tract infections
we investigated the bile-mediated protective effect in more
detail.
TABLE 1 | Oligonucleotides used in qRT-PCR experiments.
ECE1 Forward: ACAGCCATGACTTCTGTTGC
Reverse: ATCTGGAACGCCATCTCTCT
UME6 Forward: TGGTAATGGCACTAACACCAA
Reverse: TGTAATCCAAATTTAGCACAACC
HWP1 Forward: CCAGGTGCTTCTTCTTCTCC
Reverse: TAATTGGCAGATGGTTGCAT
HGC1 Forward: CAATTCTTCAACGTCATTAGGG
Reverse: GCATTTGTGGTGGTGGTATC
EFB1 Forward: GTCGACTTGTTCGGTTCTGA
Reverse: TTCGATAGCTTTGACGTTGG
ACT1 Forward: ATGGACGGTGGTATGTTTTAG
Reverse: GAACAATGGATGGACCAGATTCGTCG
MATERIALS AND METHODS
Strains and General Culture Conditions
If not indicated otherwise, C. albicans strain SC5314 was used
throughout all experiments. For studies on Tye7, strain SN152
tye71/1 and the corresponding wild-type strain SN152 were
used (Noble and Johnson, 2005; Homann et al., 2009). Pre-
cultures were grown over night at 30◦C in 20 ml YPD medium
(per liter: 10 g yeast extract, 20 g peptone, and 20 g glucose).
Cells were harvested by centrifugation at 4000 × g, washed
twice in phosphate-buffered saline (PBS) and suspended in either
YPD or MOPS-buffered RPMI 1640 (Sigma) with 2% glucose
(per liter: 10.4 g RPMI 1640, 34.53 g MOPS, 20 g glucose; pH
6.8; subsequently defined as RPMI medium). Stock solution of
caspofungin (5 mg/ml; Cancidas R©, Merck, Germany), flucytosine
(10 mg/ml), cycloheximide (20 mg/ml; Sigma C7698) or sodium
azide (20 mg/ml) were prepared in PBS and filter sterilized.
Amphotericin B stock solution was prepared at 4 mg/ml in
DMSO. Fluconazole solution at 2 mg/ml was purchased from B.
Braun, Germany. All drugs were diluted in the respective media
that were used for sensitivity analyses. Controls were prepared
according to the solvents used for stock solutions of the respective
antibiotics.
Preparation of Bile and Bile Salt
Containing Media
Bile stock solution (12.5%) was prepared by dissolving crude
porcine bile extract (Sigma, B8631) in RPMI or YPD. Insoluble
components were removed by centrifugation at 12000 × g,
the supernatant filter sterilized and stored at 4◦C in the dark.
Sodium taurodeoxycholate hydrate (Sigma, T0875), taurocholic
acid sodium salt hydrate (Sigma, T4409), sodium glycocholate
hydrate (Sigma, G7132), and unconjugated bile salts (UBS)
(Sigma 48305, 50% cholic acid sodium salt and 50% deoxycholic
acid sodium salt) were dissolved at 100 mg/ml in either YPD or
RPMI, filtered and used as stock solutions.
Drug Resistance Analyses
Antifungal drug resistance or toxicity of bile salts was tested
in broth dilution assays. Precultures of C. albicans yeasts
were grown for 16 h in liquid YPD, harvested by 10 min
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FIGURE 1 | Antifungal resistance against caspofungin and amphotericin B in presence of bile and bile extracts. Experiments were performed in biological
and technical triplicates and mean values are shown. (A) Caspofungin resistance in RPMI/glucose medium with (left) and without (right) addition of bile. (B) Same as
in (A), but with amphotericin B. (C) Endpoint analysis (20 h) of caspofungin (5 µg/ml) resistance in presence of heat-inactivated (autoclaved) and native reconstituted
bile in RPMI/glucose medium. (D) Endpoint analysis of caspofungin resistance (1 µg/ml) in presence of an ethylacetate extract made from crude bile. Bar diagrams
in (C) and (D) represent mean + SD. Significance was calculated using the two-tailed Student’s t-test (∗∗∗p < 0.005, NS = not significant).
centrifugation at 4000 × g and washed twice in PBS. Dilutions
of bile or bile salts with or without antifungals were prepared
in either RPMI medium or YPD and transferred to 96-well
plates. C. albicans cells were pre-diluted in the respective growth
medium and added to a final concentration of 4 × 104 yeasts
in 200 µl medium. NaCl in YPD was used to test the effect
of ionic strength. pH effects were tested in RPMI medium
with MOPS buffer adjusted to different pH values. Resistance
against 1 µg/ml caspofungin was evaluated in the presence
of either 2.5 mg/ml sodium taurodeoxycholate or 10 mg/ml
sodium taurocholate. All plates were sealed with transparent
gas permeable moisture barrier seal (4titude) and incubated at
37◦C for 20 h, with OD600 measurements every 15 min preceded
by 5 s shaking. Analyses were performed in triplicates with at
least one biological replication. Data were analyzed by Microsoft
Excel, and either growth curves or end point determinations are
shown.
Pre-adaptation Analyses
Candida albicans cells were pre-incubated in YPD medium for
16 h at 30◦C in the presence of 12.5% (w/v) bile or 25 mg/ml
sodium taurocholate (TC). Cells were washed once in PBS and
transferred at an OD600 of 0.1 into 96-well plates containing
MOPS-buffered RPMI with 2% glucose medium and different
concentrations of amphotericin B or caspofungin and growth
curves were recorded.
Microarray Analyses
YPD-grown cells were washed with PBS and transferred at
OD600 of 0.1 to MOPS-buffered RPMI 2% glucose medium
and grown for 4 h at 37◦C on a rotary shaker at 180 rpm.
Subsequently, parallel cultures were supplemented with either
25 mg/ml TC or left as controls. Cells were harvested by
centrifugation at 0.5 and 2 h and directly subjected to RNA
extraction as previously described (Ramachandra et al., 2014).
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FIGURE 2 | Effect of unconjugated and conjugated bile salts on growth of Candida albicans. Mean data from three independent experiments are shown.
Assays were performed in YPD or RPMI medium. (A) Growth in the presence of a serial dilution of unconjugated bile salts (UBS) consisting of a 1:1 mixture of
sodium cholate and sodium deoxycholate. (B) Growth in presence of sodium taurocholate (TC). (C) Growth in presence of sodium glycocholate (GC). (D) Yeast cells
were grown in the presence of 2 mg/ml UBS and different concentrations of TC. Bar diagrams show the mean + SD. Significance was calculated by two-tailed
Student’s t-test (∗∗∗p < 0.005).
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FIGURE 3 | Caspofungin and amphotericin B protection by bile, tauro- and glycocholate. C. albicans yeast cells were cultivated in presence of a fixed
concentration of caspofungin (CAS, 1 µg/ml) or amphotericin B (AMB, 0.5 µg/ml in RPMI and 2 µg/ml in YPD medium). Serial dilutions of either bile, taurocholate
(TC) or glycocholate (GC) were added. Endpoint determinations after 20 h at 37◦C are shown. (A) Analyses performed in YPD medium. (B) Analyses performed in
RPMI/glucose medium. Bar diagrams show mean values + SD from three independent experiments. Statistical analyses were performed by using the two-tailed
Student’s t-test (∗∗∗p < 0.005).
Microarrays were performed with Cy5-CTP labeled cRNA
(GE Healthcare) using RNA from an exponentially growing
C. albicans YPD liquid culture as Cy3-labeled common reference.
Hybridisation, scanning and data analysis were performed as
described (Ramachandra et al., 2014). The data was LOWESS
normalized and evaluated using the GeneSpring GX software
package, version 12.1 (Agilent). GO-Term analysis based on
genome annotations from the Candida Genome Database (Inglis
et al., 2012) was performed with the same program. Gene
transcription data was deposited at the ArrayExpress database1
under accession number E-MTAB-5277.
Quantitative Real Time PCR Analyses
C. albicans yeast cells were incubated for 4 or 20 h at 37◦C
in MOPS-buffered RPMI 2% glucose medium in presence or
absence of 10 mg/ml TC. Cells were harvested by centrifugation,
directly frozen in liquid nitrogen and RNA was extracted as
described above. cDNA was produced by RevertAid Reverse
Transcriptase (Thermo Scientific) with anchored oligo(dT)
primers. qRT-PCR was analyzed on a CFX384 Touch Real-
Time PCR Detection System (BioRad, Munich, Germany)
using EvaGreen 5 × qPCR (ROX) mix (Bio & Sell, Feucht,
Germany). The ACT1 and EFB1 genes served as reference for
1www.ebi.ac.uk/arrayexpress
TABLE 2 | Expression of sulfur metabolism-related genes in Candida
albicans.
Selected genes TC (0.5 h)1 RPMI (0.5 h) TC (2 h)1 RPMI (2 h)
MET2a −2.31 −1.57 −2.52 −1.28
MET3b −3.39 −1.86 −2.41 1.24
MET10c −11.68 −5.22 −9.38 −1.93
MET14d −2.06 −1.63 −2.43 −1.16
MET15e −5.37 −3.11 −2.69 1.04
MET16f −2.48 −1.86 −2.10 −1.80
Expression levels are normalized against RNA from an exponentially growing YPD
culture that was used as common reference.
1TC = 25 mg/ml.
aHomoserine acetyltransferase; bATP sulfurlyase of sulfate assimilation; csulfite
reductase; dputative adenylylsulfate kinase; eO-acetylhomoserine O-acetylserine
sulfhydrylase; fputative 3’-phosphoadenylsulfate reductase.
normalization. Normalized transcript levels were expressed as
fold expression = 12(reference −target) based on expression levels
in absence of TC. Oligonucleotide sequences are provided in
Table 1.
Farnesol Effects in Presence of
Taurocholic Acid
A 200 mM ethanolic stock solution of trans, trans farnesol was
diluted 1000-fold in MOPS-buffered RPMI 2% glucose medium
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FIGURE 4 | Effect of tye7 gene deletion and pre-adaptation to bile or
taurocholic acid on protection against antifungals. All data represent
mean values + SD from three independent experiments and endpoint data
after 20 h of incubation are shown. (A) Wild type (WT) and 1/1tye7 mutant
were grown in RPMI/glucose medium with or without 25 mg/ml taurocholate
(TC) and varying concentrations of caspofungin (0, 0.5, 1 µg/ml). (B,C)
C. albicans yeast cells were pre-incubated in YPD medium with or without
25 mg/ml taurocholate (TC) or 12.5 mg/ml bile. For sensitivity testing wells
were inoculated at an OD600 of 0.1 (dashed line) and varying concentrations
of (B) caspofungin or (C) amphotericin B were added. Growth was assessed
after 20 h of incubation. Statistical significance was calculated by using the
two-tailed Student’s t-test (∗∗∗p < 0.005, NS = not significant).
in presence or absence of 10 mg/ml TC. Shake flask cultures
(5 ml) were inoculated with C. albicans yeasts at an OD600 of
0.1 and incubated at 37◦C and 180 rpm. Samples were removed
at various time points and subjected to microscopy on a Zeiss
AxioImager M1.
TABLE 3 | Expression of hyphae-associated genes in C. albicans.
Selected genes TC (0.5 h)1 RPMI (0.5 h) TC (2 h)1 RPMI (2 h)
ECE1a 14.56 1.39 27.49 3.14
HWP1b 1.15 −1.05 3.70 1.48
HYR1c 2.61 2.10 2.29 2.24
SOD5d 4.08 1.28 6.54 1.70
IHD1e −1.55 −1.24 1.22 −1.25
RBT1f 1.28 1.15 1.53 1.26
Expression levels are normalized against RNA from an exponentially growing YPD
culture that was used as common reference.
1TC = 25 mg/ml.
aHyphal-specific cell wall protein; bhyphal cell wall protein; chyphal-induced GPI-
anchored cell wall protein; dcopper- and zinc-containing superoxide dismutase
(induced by hyphal growth); eputative GPI-anchored protein (greater transcription
in hyphal than yeast); fcell wall protein with similarity to Hwp1p.
FIGURE 5 | Expression of hyphae-specific genes in the presence of
conjugated bile salts. Expression of hyphae-specific genes ECE1, UME6,
HWP1, and HCG1 was analyzed by qRT-PCR and normalized against actin
gene (ACT1) expression. Cells were grown at 37◦C in RPMI/glucose medium
with or without the addition of 10 mg/ml taurocholate (TC). (A) Expression
analysis at 4 h from three biological replicates in technical duplicates. Bar
diagrams show mean values + SD. Statistical significance was calculated by
using the two-tailed Student’s t-test with ∗p < 0.05 and ∗∗p < 0.01.
(B) Expression analysis at 20 h from one biological sample as technical
duplicate.
Rhodamine 6G and Crystal Violet In- and
Efflux Analyses
Candida albicans yeasts were incubated at 30◦C in MOPS-
buffered RPMI 2% glucose medium in the presence of 1 µM
Rhodamine 6G (R6G) and various concentrations of bile or
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FIGURE 6 | Morphology of C. albicans in the presence of taurocholic acid and farnesol. C. albicans yeast cells were incubated in RPMI medium at 37◦C in
the absence or presence of 10 mg/ml taurocholate, 200 µM farnesol or combinations thereof. Morphology was analyzed by light microscopy at the time of
inoculation and at 3, 6, and 24 h.
conjugated bile salts. Aliquots were harvested at different
time points, washed twice with 50 mM HEPES buffer pH
7.0. R6G fluorescence was measured in a microplate reader
(Fluostar Omega, BMG Labtech) at 545 nm excitation and
590 nm emission. Fluorescence was normalized against OD600.
For R6G eﬄux analyses, C. albicans yeasts were loaded for
30 min at 30◦C with 1 µM R6G. Yeast cells were collected
by centrifugation and suspended in fresh media containing
1 µM R6G supplemented with either bile, sodium taurocholate
or sodium taurodeoxycholate (all at final concentration of
5 mg/ml) or left without supplementation. At different time
points cells were harvested and washed once in HEPES buffer.
The eﬄux of R6G was determined from the relative decrease
of fluorescence from OD600 normalized cell densities. For
crystal violet (CV) absorption analyses yeasts were incubated for
30 min at 30◦C in MOPS-buffered RPMI 2% glucose medium
containing 2 or 4 µg/ml CV. As indicated media contained
5 mg/ml bile or conjugated bile salts and different concentrations
(0–80 mg/ml) of NaCl. Uptake of CV was visualized by
photographs of cell pellets. Absorption rate was quantified at
590 nm from supernatants after cell removal and compared
to mock-inoculated medium. Relative CV absorption (%) was
calculated from (A590control−A590sample)/A590control × 100.
Determination of CMC Values
Critical micelle concentration (CMC) was determined as
previously described (Patist et al., 2000) based on the change
of absorbance of eosin Y during formation of micelles. In brief,
19 µM of eosin Y were mixed with different concentrations of
either bile or taurine conjugated bile salts and absorbance was
measured at 542 nm in a 96-well plate using a microplate reader
(Fluostar Omega, BMG Labtech). Absorbance was plotted against
the log concentration of the solubilising agent for calculation of
the CMC.
Statistical Analyses
Results in bar diagrams are shown as mean ± standard
deviation (SD). Growth curves depict mean values from technical
and biological replicates. All experiments were performed in
biological duplicates or triplicates with two or three wells
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FIGURE 7 | Uptake and efflux of rhodamine 6G and crystal violet (CV) in the presence of bile or conjugated bile salts. All data represent mean
values + SD from three independent experiments. The Student’s t-test was used for calculation of statistical significance (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.005,
NS = not significant). (A) Time-dependent rhodamine 6G (R6G) uptake by C. albicans cells in the presence of serial dilutions of either taurocholate (TC), bile or
taurodeoxycholate (TDC). Cells were harvested at indicated time points, washed and OD600-normalized R6G fluorescence was measured. Low fluorescence
indicates low R6G absorption. Curves with asterisks indicate concentrations of TC (5 mg/ml), bile (1.25 mg/ml), and TDC (1.25 mg/ml) at which absorption
significantly differs from the control. (B) R6G efflux assay. Yeast cells were pre-loaded with 1 µM R6G and shifted to R6G-containing media containing a fixed
concentration (5 mg/ml) of either TC, bile or TDC. Efflux in presence of bile or TDC is significantly faster than with TC. (C) CV absorption by C. albicans in the
presence or absence of 5 mg/ml of TC, TDC or bile. Inlay shows cell pellets after 30 min incubation with 2 µg/ml CV. The bar diagram shows the relative CV
absorption from culture supernatants after 30 min of incubation in the presence of 4 µg/ml CV.
inoculated in parallel. Statistical significance was calculated using
the two-tailed Student’s t-test.
RESULTS
Proteins, Phospholipids, and Cholesterol
Do Not Protect against Antifungals
Resistance analyses were performed in broth dilution assays
in which porcine bile (6% w/v) was tested for its protective
effect against caspofungin (CAS) and amphotericin B (AMB). As
shown in Figures 1A,B, C. albicans was sensitive against CAS at
1.25 µg/ml (MIC 0.125 mg/l), but nearly completely protected in
the presence of bile even at 20 µg/ml. Similarly, C. albicans was
sensitive at 0.25 µg/ml AMB (MIC = 0.063 mg/l), but protected
in the presence of bile although protection against AMB was less
pronounced compared to CAS.
Bile solids consist of about 60% bile salts, 12% fatty acids,
9% cholesterol, 7% proteins, and 3% phospholipids and bilirubin
(Farina et al., 2009). To elucidate the contribution of bile proteins
(Dietschy, 1968; Pasternak et al., 2014) in protection, bile was
heat-inactivated by autoclaving. Autoclaved bile showed the
same protection as non-treated bile, indicating that no heat-
sensitive compounds were required for protection (Figure 1C).
Furthermore, an ethyl acetate extract prepared from bile did
not protect against CAS (Figure 1D). These analyses imply that
neither proteins nor fatty acids, phospholipids or cholesterol are
protective against antifungals.
Conjugated Bile Salts Are Well Tolerated
by C. albicans
Based on analyses above, we focused on conjugated and
unconjugated bile salts. First, sensitivity analyses of C. albicans
against possible toxic effects of unconjugated choline and
deoxycholine in comparison to taurine and glycine conjugated
choline were performed in YPD and RPMI medium (Figure 2).
A mixture of choline and deoxycholine restricted growth in both
media with an MIC of about 1.56 mg/ml (Figure 2A). In contrast,
conjugated choline up to a concentration of at least 50 mg/ml
was well tolerated, and no difference between taurocholate (TC)
and glycocholate (GC) was observed (Figures 2B,C). Even more,
5 mg/ml of TC neutralized the toxic effects of 2 mg/ml of UBS
(Figure 2D). Since conjugation of bile salts occurs directly within
liver cells located at the periportal region of the liver conjugated
bile salts are predominantly found in bile fluids (Solaas et al.,
2000) with a concentration of about 40 mM (Begley et al., 2005).
De-conjugation mainly occurs within the intestine by bacterial
degradation (Begley et al., 2005). Therefore, although bile fluids
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FIGURE 8 | Micelle formation and antifungal protection. All diagrams show mean values + SD from three independent experiments. (A) Determination of the
critical micellar concentration (CMC) of TC, TDC and bile by using an eosin Y assay. CMC values were calculated from trend lines based on the logarithm of the
sample concentration against absorbance at 542 nm. (B) Effect of increasing ionic strength on the CMC of TC. (C) Effect of increasing salt concentration on
TC-mediated protection against caspofungin (CAS). Media contain a fixed concentration of either 10 mg/ml TC, 2 µg/ml CAS or a combination of both. (D) Effect of
pH on TC- (10 mg/ml) and TDC- (2.5 mg/ml) mediated protection against 1 µg/ml CAS. Data were normalized against control growth in the absence of CAS. (E) CV
absorption in the presence of 5 mg/ml TC at different ionic strength. Inlay photo shows the NaCl-dependent decolourisation of cell pellets. The bar diagram
visualizes the relative CV absorption from the culture medium after 30 min of incubation. Statistical analyses were performed by the two-tailed Student’s t-test
(∗p < 0.05, ∗∗∗p < 0.005, NS = not significant).
within the intestine may contain a significant proportion of
UBS, their toxic effects on C. albicans can be neutralized by the
remaining conjugated bile salts.
Conjugated Bile Salts Confer Resistance
of C. albicans against Antifungals
To determine the protective effect of conjugated bile salts in
comparison to bile, sensitivity tests in YPD (Figure 3A) and
RPMI/glucose medium (Figure 3B) against CAS and AMB were
performed. Indeed both, TC and GC were able to protect from
antifungals in a concentration-dependent manner. Bile exhibited
a full protective effect at about 3.1–6.3 mg/ml against both drugs,
whereas a slightly higher concentration of about 12.5 mg/ml of
conjugated bile salts was required for protection.
Protection Does Not Require Expression
of Specific Resistance Associated Genes
Microarray analyses were performed to investigate the
mechanism of antifungal protection in the presence of TC. Cells
exponentially growing in YPD were shifted to RPMI/glucose
medium with or without TC and gene expression was analyzed
after 0.5 and 2 h of incubation. No clear pattern for the
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FIGURE 9 | Bile- and conjugated bile salt-mediated resistance against small and hydrophilic antifungals. Endpoint determination of growth after 20 h
incubation at 37◦C. Bile (12.5 mg/ml) and taurodeoxycholic acid (TDC, 12.5 mg/ml) or media controls were treated with serially diluted (A) fluconazole, (B)
cycloheximide, (C) flucytosine, or (D) sodium azide. Bar diagrams represent the mean values + SD from three independent experiments. The Student’s t-test was
used for calculation of statistical significance (∗∗∗p < 0.005).
upregulation of genes typically involved in drug resistance was
observed, and the drug eﬄux pumps and transporters, such as
Cdr1, Cdr2, and Mdr1 (Nakamura et al., 2001; Watamoto et al.,
2011) showed similar expression patterns in presence or absence
of TC. However, expression of genes involved in sulfur amino
acid metabolism were downregulated indicating that the sulfur
content of taurine from TC was sensed (Table 2). In contrast,
hyphae-associated genes, such as ECE1 and HWP1 as well as the
global regulator Tye7 (Askew et al., 2009) were upregulated. To
analyze the impact of Tye7 on antifungal protection a tye71/1
mutant of C. albicans (Homann et al., 2009) was tested for its
resistance against caspofungin in the presence of TC. Although
the tye7 mutant showed general reduction in growth rate,
TC-mediated resistance was comparable to that of the parental
strain (Figure 4A). Thus, Tye7 is not important for protection.
We subsequently tested if pre-incubation with bile or TC
protects C. albicans. Cells were pre-grown in the presence of TC
or bile, washed and challenged with CAS or AMB. Since both
drugs remained inhibitory (Figures 4B,C), no pre-adaptation
toward antifungals can be induced by bile or conjugated bile salts.
Conjugated Bile Salts Block Quorum
Sensing by Farnesol
Microarray experiments revealed a strong upregulation of
hyphae-specific genes in presence of TC (Table 3). qRT-PCR
analyses confirmed upregulation of hyphae-associated genes after
the transfer to TC containing medium at 4 and 20 h (Figure 5).
This high gene expression levels during prolonged incubation
was unexpected since C. albicans produces the quorum sensing
molecule farnesol that triggers the reversal to yeast cells when
exceeding a certain threshold level (Ramage et al., 2002; Langford
et al., 2009). Therefore, morphological analyses were performed
in RMPI/glucose medium, which triggers the initial formation
of hyphae. Control cells cultivated without either farnesol or
TC showed the expected morphological transitions (Figure 6):
Pseudo- and true hyphae formed at early time points with
an accumulation of hyphae after 6 h. However, after 24 h a
mixture of yeast and hyphal cells was detected, indicating a
functional quorum sensing mechanism. Cells cultivated in the
presence of TC formed hyphae at early time points that failed to
switch back to yeast cells, and a 24 h culture consisted solely of
hyphae (Figure 6). In contrast, cells cultivated in the presence of
farnesol remained in yeast form throughout the 24 h observation
period (Figure 6). In the presence of both, farnesol and TC the
transition to hyphae was slightly delayed compared to TC alone.
However, hyphae were produced and even after 24 h only small
numbers of yeast cells were observed (Figure 6). This indicates
that TC efficiently blocks farnesol signaling and implies that
a similar mechanism might hold true for the protection from
antifungals. However, it should be mentioned that TC by itself
does not act as a stimulus for hyphae formation. When cells
were cultivated in YPD medium no transition into the hyphal
morphology was observed by the addition of TC (not shown).
Therefore, experiments on drug sensitivity performed in YPD
medium resemble planktonic yeast growth, whereas those in
RPMI medium resemble hyphal growth within tissues.
Bile and Conjugated Bile Salts Block
Rhodamine 6G and Crystal Violet
Absorption
Rhodamine 6G (R6G) is a fluorescent dye that is used as a
model compound in drug influx and eﬄux studies (Nakamura
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et al., 2001; Saengkhae et al., 2003). In- and eﬄux of R6G was
investigated in the presence of bile, TC or taurine conjugated
deoxycholic acid (TDC), another major bile component. As
shown in Figure 7A, influx of R6G was blocked by all three
additives, although a clear dependence on the specific bile
compound was observed. While at least 5 mg/ml of TC were
required to block the uptake of R6G, 1.25 mg/ml of bile or TDC
already blocked influx. Similarly, all three compounds triggered
the eﬄux of R6G when applied at a concentration of 5 mg/ml,
with a significantly faster eﬄux in presence of bile or TDC
than with TC (Figure 7B). These results suggested that bile and
conjugated bile salts can protect C. albicans from antifungals in a
dose-dependent manner by interacting with drugs in the growth
medium. Results also implied that TDC might possess a higher
protective potential than TC. Indeed, when antifungal protection
against amphotericin B and caspofungin was tested with all three
compounds, bile and TDC required the same concentration for
protection (2.5 mg/ml for amphotericin B and 5 mg/ml for
caspofungin), whereas higher concentrations were required for
protection by TC (10 mg/ml). Finally, when the absorption of
the toxic compound CV was investigated, TC, TDC and bile
significantly reduced CV absorption, with TDC and bile being
more effective than TC (Figure 7C).
Critical Micelle Concentration Correlates
with Antifungal Protection
Bile solubilises hydrophobic and amphiphilic molecules by
forming mixed micelles (Begley et al., 2005). However, micelle
formation only occurs when a so-called critical micellar
concentration (CMC) is exceeded. Due to the different
concentrations of bile, TC and TDC required in the R6G and
CV in- and eﬄux experiments, CMC values were determined
for all three compounds (Figure 8A). Indeed, CMC values of
bile and TDC were significantly lower than that of TC with bile
showing the lowest CMC. To confirm that CMC determines
protection, conditions that reduce CMCs such as increased salt
concentration or lowered pH were tested (Sugihara et al., 1982)
(Figure 8B). Indeed, lower concentrations of TC or TDC were
required for protection against CAS when either ionic strength
was increased or the pH lowered (Figures 8C,D). Similarly,
absorption of CV in presence of 5 mg/ml TC was reduced
when the salt concentration was increased (Figure 8E). This
confirms trapping of antifungals in micelles, thereby reducing
their bioavailability.
Small and Hydrophilic Drugs Remain
Active in Presence of Conjugated Bile
Salts
As bile and conjugated bile salts are very effective in
solubilising hydrophobic and amphiphilic compounds, we
assumed that small and hydrophilic compounds might be
less efficiently trapped in micelles. Therefore, the protective
effect against other antifungal compounds, such as fluconazole,
cycloheximide, flucytosine, and sodium azide was tested. The
efficacy of fluconazole was dramatically decreased in the presence
12.5 mg/ml bile, whereas the same concentration of TDC was
not protective (Figure 9A). When cycloheximide (Figure 9B),
flucytosine (Figure 9C), or sodium azide (Figure 9D) were tested,
neither bile nor TDC were protective. This suggests that bile and
conjugated bile salts cannot efficiently trap small and hydrophilic
compounds in mixed micelles.
DISCUSSION
Recently, studies on a murine infection model showed that
C. albicans is protected from antifungals inside the gall bladder
and shed cells survive the passage through the bile duct
and intestine (Jacobsen et al., 2014). Therefore, gall bladder
colonization in patients might act as a reservoir for re-
colonization of the intestine after discontinuation of antifungal
therapy. Here, we show the relevance of micelle formation by
conjugated bile salts as the major mechanism of protection.
Bile salts have the potential to inactivate pathogens (Hofmann,
1999) and, in agreement, UBS showed toxic effects on C. albicans.
However, conjugation of bile salts with either taurine or glycine
reduced their toxicity and, in a mixture, were able to detoxify
UBS. Therefore, conjugation of bile salts seems essential for
C. albicans to colonize the gall bladder. However, a specific
transcriptional response toward conjugated bile salts seems
of minor importance for the protection from antifungals.
Despite upregulation of glycolysis and hyphae-associated genes
no clear pattern for the upregulation of resistance-associated
genes was observed (Mathe and Van Dijck, 2013). Some of the
observed changes in gene expression may result from blocking
of the quorum sensing molecule farnesol (Wongsuk et al.,
2016), which is in agreement with the early formation of true
hyphae and cultures remaining in hyphal morphology even at
high cell densities. This effect of conjugated bile salts could
possibly counteract the known synergistic effects of farnesol with
antifungals in the treatment of fungal (Katragkou et al., 2015) or
mixed species (Fernandes et al., 2016) biofilms.
In our experiments bile or conjugated bile salts prevented
influx and promoted eﬄux of drugs as shown for the model
compounds R6G and CV. While bile salts can act as so-
called “enabling formulations” to increase the bioavailability
of drugs with poor dissolution characteristics (Buckley et al.,
2013), bioavailability requires the release of drugs from micelles
for crossing membranes of target cells. This is dependent on
the equilibrium of drugs free in solution and drugs bound in
micelles (Yano et al., 2010). However, significant differences in the
encapsulation capability between bile and its conjugated bile salts
seem to exist. When testing 30 different compounds, free drug
concentration of some compounds was reduced by either bile
or a mixture of taurocholate and lecithin, whereas other drugs
were only encapsulated by bile (Berginc et al., 2012). This reflects
our investigations, in which CAS and AMB were encapsulated
by both, bile and conjugated bile salts, whereas fluconazole
remained active with TC or TDC, but was inactivated by bile.
This may be a result of the more complex composition of bile,
which forms more variable mixed micelles that possess higher
drug binding capacities than those made of pure conjugated
bile salts. The presence of cholesterol in bile samples may
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also at least partially contribute to the increased protective
effect of bile against fluconazole. Investigations on Aspergillus
fumigatus showed that cholesterol increased resistance against
itraconazole by incorporation of cholesterol into the fungal
cell membrane. However, a much lower protective effect was
observed when voriconazole was used, which indicates that
cholesterol incorporation on its own is not sufficient for a general
azole resistant phenotype (Xiong et al., 2005). In this respect, it
should be noted that the ethyl acetate extract of bile containing
phospholipids, fatty acids and cholesterol was not protective
against various drugs tested. Nevertheless, future studies will
have to investigate the increased efficiency of drug inactivation
from mixed micelles by combining conjugated bile salts with
phospholipids, unsaturated fatty acids and cholesterol.
Caspofungin, which shows excellent efficacies in treatment of
systemic infections gets inactivated by bile and bile salts and,
in agreement, failed in a case series for treatment of biliary
tract infections (Domagk et al., 2006). In addition, a recent
study on fungal cholangitis patients after liver transplantation
revealed a reduced bioavailability of different AMB formulations
in bile. The maximum concentration of AMB detected in one
of the human bile samples was 1.28 mg/l, but in vitro studies
showed that up to 5 mg/l of AMB added to human bile samples
did not inactivate C. albicans or other Candida species leading
to the conclusion that a reliable treatment success on fungal
cholangitis with AMB cannot be anticipated (Welte et al., 2015).
This underlines our results on the reduced bioavailability of
antifungals by micelle formation. Importantly, a recent study on
echinocandin resistant Candida spp. in liver transplant recipients
revealed the emergence of resistant isolates within one months
after initiation of treatment (Prigent et al., 2016). At least three
resistant C. albicans isolates were isogenic to susceptible isolates
from the same patient, indicating that resistance occurred under
the selective pressure of echinocandin treatment. While some
resistant Candia spp. were isolated from multiple body site,
resistant isolates were overrepresented in samples collected from
the anus region. It was speculated that sub-inhibitory drug
concentrations may be present in the digestive system promoting
the emergence of resistance (Prigent et al., 2016). In our previous
study (Jacobsen et al., 2014), we found that C. albicans cells
persisting under antifungal therapy in the gall-bladder are shed
by bile and survive the intestinal passage. This shedding possibly
leads to a re-colonization of the intestine. In agreement with
the speculation above, encapsulation of drugs in micelles lowers
their bioavailability to a sub-inhibitory concentration that might
indeed facilitate the emergence of resistant isolates either directly
within the biliary system or in the intestine. If this holds true,
efficient monitoring of fungal bile infections in patients at risk
for invasive fungal infections should be considered.
The strong reduction of antifungal efficacy of several drugs
in the presence of bile may make it difficult to resolve fungal
infections within the biliary tract. However, neither bile nor
conjugated bile salts were able to efficiently encapsulate small
and hydrophilic compounds, such as cycloheximide, flucytosine,
or sodium azide. Therefore, if susceptibility profiling allows,
antifungals that are difficult to trap in micelles should be
considered when treating fungal infections of the biliary tract.
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